AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8294833 — intervention group
Group type: EXPERIMENTAL
Intervention: Forearm tourniquet (in clinical cases)
Number of subjects: 40
Study 8294833 — intervention group
Group type: COMPARATOR
Intervention: Tourniquet times less than 30 minutes
Number of subjects: 40
Study 2883695 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (0.057 mg/kg)
Number of subjects: 8
Study 2883695 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (0.029 mg/kg)
Number of subjects: 8
Study 2883695 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0.286 mg/kg)
Number of subjects: 8
Study 2883695 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.000 mg/kg)
Number of subjects: 8
Study 2883695 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (0.028 mg/kg)
Number of subjects: 8
Study 2883695 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (0.014 mg/kg)
Number of subjects: 8
Study 2883695 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0.143 mg/kg)
Number of subjects: 8
Study 29595304 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing a letter to their future self (either three months or 20 years into the future)
Number of subjects: 0
Study 29595304 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 26180052 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-tDCS at 1 mA for 10 minutes
Number of subjects: 27
Study 26180052 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-tDCS at 1 mA for 20 minutes
Number of subjects: 27
Study 26180052 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-tDCS at 2 mA for 10 minutes
Number of subjects: 27
Study 26180052 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-tDCS at 2 mA for 20 minutes
Number of subjects: 27
Study 26180052 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation of LTA and DLPFC
Number of subjects: 27
Study 24911577 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorediplon 5 mg
Number of subjects: 35
Study 24911577 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorediplon 10 mg
Number of subjects: 35
Study 24911577 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorediplon 1 mg
Number of subjects: 35
Study 24911577 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem 10 mg (active control)
Number of subjects: 35
Study 24911577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 22419350 — intervention group
Group type: EXPERIMENTAL
Intervention: POIO (preoperative and intraoperative dose)
Number of subjects: 240
Study 22419350 — intervention group
Group type: EXPERIMENTAL
Intervention: POIOPO (preoperative, intraoperative, and postoperative doses)
Number of subjects: 240
Study 22419350 — intervention group
Group type: EXPERIMENTAL
Intervention: LA (local application)
Number of subjects: 240
Study 22419350 — intervention group
Group type: EXPERIMENTAL
Intervention: IO (intraoperative dose only)
Number of subjects: 240
Study 22419350 — intervention group
Group type: EXPERIMENTAL
Intervention: IOPO (intraoperative and postoperative doses)
Number of subjects: 240
Study 22419350 — intervention group
Group type: COMPARATOR
Intervention: Control (no tranexamic acid)
Number of subjects: 240
Study 20804368 — intervention group
Group type: EXPERIMENTAL
Intervention: Cs-4 (Cordyceps sinensis) 333 mg, taken 3 times a day for 12 weeks
Number of subjects: 20
Study 20804368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 18000183 — intervention group
Group type: EXPERIMENTAL
Intervention: Coccinia cordifolia extract (1 g alcoholic extract for 90 days)
Number of subjects: 60
Study 18000183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15930077 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy plus olanzapine (mean dose 8.83 mg/day)
Number of subjects: 60
Study 15930077 — intervention group
Group type: COMPARATOR
Intervention: Dialectical behavior therapy plus placebo
Number of subjects: 60
Study 12830102 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based nurse case managers
Number of subjects: 106
Study 10584567 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA 1,200 mg
Number of subjects: 73
Study 10584567 — intervention group
Group type: COMPARATOR
Intervention: MPA 600 mg
Number of subjects: 73
Study 8674893 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, low-cholesterol diet, high polyunsaturated/saturated fatty acid ratio, and calorie restriction
Number of subjects: 14
Study 8674893 — intervention group
Group type: COMPARATOR
Intervention: No dietary change
Number of subjects: 14
Study 2060176 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium clodronate
Number of subjects: 13
Study 2060176 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 13
Study 6863091 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (500 mg) administered orally
Number of subjects: 5
Study 6863091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 31752105 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegan Diet (VD)
Number of subjects: 53
Study 31752105 — intervention group
Group type: COMPARATOR
Intervention: Meat-Rich Diet (MD)
Number of subjects: 53
Study 29020589 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAd3‐EBO‐Z vaccine
Number of subjects: 1500
Study 29020589 — intervention group
Group type: EXPERIMENTAL
Intervention: rVSV∆G‐ZEBOV‐GP vaccine
Number of subjects: 1500
Study 29020589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1500
Study 26560243 — intervention group
Group type: COMPARATOR
Intervention: Adaptive control (Ossur Rheo Knee II)
Number of subjects: 12
Study 26560243 — intervention group
Group type: COMPARATOR
Intervention: Active control (Ossur Power Knee II)
Number of subjects: 12
Study 26560243 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive control (existing knee)
Number of subjects: 12
Study 23431996 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG-Fresenius (9 mg/kg body weight)
Number of subjects: 52
Study 23431996 — intervention group
Group type: COMPARATOR
Intervention: Control (no induction therapy)
Number of subjects: 52
Study 23431996 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG-Fresenius
Number of subjects: 52
Study 23431996 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 52
Study 20584798 — intervention group
Group type: EXPERIMENTAL
Intervention: Early continuous positive airway pressure (CPAP)
Number of subjects: 39
Study 20584798 — intervention group
Group type: COMPARATOR
Intervention: Mechanical ventilation
Number of subjects: 39
Study 19584690 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus with reduced cyclosporine A (CsA) (trough level 3-8 ng/mL)
Number of subjects: 176
Study 19584690 — intervention group
Group type: COMPARATOR
Intervention: MMF (3 g/day) with standard CsA
Number of subjects: 176
Study 19584690 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 176
Study 19584690 — intervention group
Group type: COMPARATOR
Intervention: MMF
Number of subjects: 176
Study 15991090 — intervention group
Group type: EXPERIMENTAL
Intervention: lipo‐PGE 1
Number of subjects: 128
Study 15991090 — intervention group
Group type: COMPARATOR
Intervention: Control (methylprednisolone only)
Number of subjects: 128
Study 15991090 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 128
Study 12514304 — intervention group
Group type: EXPERIMENTAL
Intervention: CLA-mix (8.0 g daily, 76% pure CLA)
Number of subjects: 21
Study 12514304 — intervention group
Group type: COMPARATOR
Intervention: Safflower oil (placebo, 8.0 g daily)
Number of subjects: 21
Study 12514304 — intervention group
Group type: EXPERIMENTAL
Intervention: t10c12-CLA
Number of subjects: 21
Study 12514304 — intervention group
Group type: EXPERIMENTAL
Intervention: c9t11-CLA
Number of subjects: 21
Study 10561291 — intervention group
Group type: EXPERIMENTAL
Intervention: CODE (cisplatin, vincristine, doxorubicin, etoposide)
Number of subjects: 219
Study 10561291 — intervention group
Group type: COMPARATOR
Intervention: CAV/EP (cyclophosphamide, doxorubicin, vincristine/etoposide, cisplatin)
Number of subjects: 219
Study 10561291 — intervention group
Group type: EXPERIMENTAL
Intervention: CODE
Number of subjects: 219
Study 10561291 — intervention group
Group type: COMPARATOR
Intervention: CAV/EP
Number of subjects: 219
Study 8762417 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhikang Oral Liquid (ZK)
Number of subjects: 70
Study 8762417 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 1676675 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 5 mg (B5)
Number of subjects: 7
Study 1676675 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 10 mg (B10)
Number of subjects: 7
Study 1676675 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 20 mg (B20)
Number of subjects: 7
Study 1676675 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg (A50)
Number of subjects: 7
Study 1676675 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg (A100)
Number of subjects: 7
Study 1676675 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol 40 mg (N40)
Number of subjects: 7
Study 1676675 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 7
Study 1676675 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline-induced tachycardia with bisoprolol
Number of subjects: 7
Study 1676675 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline-induced tachycardia with atenolol
Number of subjects: 7
Study 1676675 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline-induced tachycardia with nadolol
Number of subjects: 7
Study 6304360 — intervention group
Group type: EXPERIMENTAL
Intervention: American Heart Association Hyperlipidemia Diet C (n = 20)
Number of subjects: 45
Study 6304360 — intervention group
Group type: COMPARATOR
Intervention: Low-fat, high-fiber, complex carbohydrate diet (similar to Pritikin Maintenance Diet, n = 25)
Number of subjects: 45
Study 31502228 — intervention group
Group type: EXPERIMENTAL
Intervention: Question Prompt List (QPL)
Number of subjects: 279
Study 31502228 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 279
Study 31022481 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise program delivered in a facility-based setting
Number of subjects: 500
Study 31022481 — intervention group
Group type: COMPARATOR
Intervention: Telerehabilitation exercise program delivered in a home-based setting
Number of subjects: 500
Study 28893753 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous stenting
Number of subjects: 130
Study 28893753 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 130
Study 27007998 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol oral tablets
Number of subjects: 100
Study 27007998 — intervention group
Group type: COMPARATOR
Intervention: Ambroxol orally-disintegrating tablets
Number of subjects: 100
Study 24035344 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.41 mg/kg
Number of subjects: 8
Study 24035344 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.71 mg/kg
Number of subjects: 8
Study 24035344 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam 2 mg
Number of subjects: 8
Study 21993937 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic duodenojejunal bypass with sleeve gastrectomy
Number of subjects: 38
Study 18981187 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral sensory stimulation (2 hours of simultaneous electrical stimulation over the median and ulnar nerves at the wrist)
Number of subjects: 20
Study 18981187 — intervention group
Group type: COMPARATOR
Intervention: Sham-control (stimulation to the level of perception)
Number of subjects: 20
Study 18981187 — intervention group
Group type: COMPARATOR
Intervention: Peripheral sensory stimulation and Sham-control
Number of subjects: 20
Study 17414939 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (0.375 mg/d to a maximum tolerated dose of ≤4.5 mg/d over a 6-week period)
Number of subjects: 144
Study 17414939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 17414939 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 144
Study 15708053 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (100 mg) taken 1 to 2 hours before VCD use
Number of subjects: 31
Study 15708053 — intervention group
Group type: COMPARATOR
Intervention: Control group (VCD alone)
Number of subjects: 31
Study 15708053 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (sildenafil + VCD)
Number of subjects: 31
Study 12218949 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (100 IU/kg body weight, subcutaneous for 6 days)
Number of subjects: 49
Study 9593384 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin surface-modified (HSM) intraocular lenses (IOLs)
Number of subjects: 25
Study 9593384 — intervention group
Group type: COMPARATOR
Intervention: Polymethylmethacrylate (PMMA) intraocular lenses (IOLs)
Number of subjects: 25
Study 8829890 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 5 mg
Number of subjects: 102
Study 8829890 — intervention group
Group type: COMPARATOR
Intervention: Flunitrazepam 1 mg
Number of subjects: 102
Study 2212123 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal platelet-activating factor (PAF-acether)
Number of subjects: 0
Study 2212123 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet activating factor antagonist BN52063
Number of subjects: 0
Study 81986 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine continued
Number of subjects: 51
Study 81986 — intervention group
Group type: COMPARATOR
Intervention: Control tablet substituted
Number of subjects: 51
Study 31651084 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot orthoses plus prescribed footwear
Number of subjects: 46
Study 31651084 — intervention group
Group type: COMPARATOR
Intervention: Prescribed footwear alone
Number of subjects: 46
Study 31495898 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid Emulsion (LE)
Number of subjects: 15
Study 31495898 — intervention group
Group type: COMPARATOR
Intervention: Solid Emulsion (SE)
Number of subjects: 15
Study 30738659 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rising BMI trajectory group
Number of subjects: 410
Study 30738659 — intervention group
Group type: COMPARATOR
Intervention: Late rising BMI trajectory group
Number of subjects: 410
Study 30738659 — intervention group
Group type: COMPARATOR
Intervention: Normal BMI trajectory group
Number of subjects: 410
Study 30738659 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI trajectory groups comparison
Number of subjects: 410
Study 28526014 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy
Number of subjects: 4768
Study 28526014 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihyperglycaemia therapy
Number of subjects: 4768
Study 28526014 — intervention group
Group type: COMPARATOR
Intervention: No lipid-lowering therapy
Number of subjects: 4768
Study 22978697 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal-ceramic crown (MC) made from a Pd‐Au‐Ag‐Sn‐In alloy and a glass‐ceramic veneer
Number of subjects: 31
Study 22978697 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-veneered (glazed) lithium disilicate glass‐ceramic crown (LDC)
Number of subjects: 31
Study 22978697 — intervention group
Group type: EXPERIMENTAL
Intervention: Veneered lithia disilicate glass‐ceramic crown (LDC/V)
Number of subjects: 31
Study 21775977 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute phenylalanine/tyrosine depletion (APTD)
Number of subjects: 47
Study 21775977 — intervention group
Group type: COMPARATOR
Intervention: Nutritionally balanced control mixture
Number of subjects: 47
Study 19216017 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading a text description of the map
Number of subjects: 0
Study 19216017 — intervention group
Group type: EXPERIMENTAL
Intervention: Touching a wooden topological representation of the map
Number of subjects: 0
Study 19216017 — intervention group
Group type: EXPERIMENTAL
Intervention: Both reading and touching the map
Number of subjects: 0
Study 16981050 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumazin (10 mg piroxicam, 1 mg dexamethasone, 35 mg orphenadrine, 2.5 mg cyanocobalamin)
Number of subjects: 80
Study 16981050 — intervention group
Group type: COMPARATOR
Intervention: Feldene (20 mg piroxicam)
Number of subjects: 80
Study 12428781 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for depression (CBT-D)
Number of subjects: 179
Study 12428781 — intervention group
Group type: COMPARATOR
Intervention: Standard smoking cessation treatment
Number of subjects: 179
Study 10453768 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic multicomponent rehabilitation strategy
Number of subjects: 304
Study 10453768 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 304
Study 8652960 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% Intralipid
Number of subjects: 37
Study 8652960 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% Intralipid
Number of subjects: 37
Study 2221287 — intervention group
Group type: EXPERIMENTAL
Intervention: Hazelden‐type treatment (N = 74)
Number of subjects: 141
Study 2221287 — intervention group
Group type: COMPARATOR
Intervention: Traditional‐type treatment (N = 67)
Number of subjects: 141
Study 349319 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (600 mg twice a day)
Number of subjects: 14
Study 349319 — intervention group
Group type: COMPARATOR
Intervention: Prindolol (15 mg twice a day) plus Hydralazine (50 mg three times a day)
Number of subjects: 14
Study 30028640 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of itraconazole 100 mg
Number of subjects: 38
Study 30028640 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of itraconazole 100 mg
Number of subjects: 38
Study 26162769 — intervention group
Group type: EXPERIMENTAL
Intervention: Needs-based patient education using the Educational Needs Assessment Tool (ENAT)
Number of subjects: 132
Study 26162769 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) received patient education without ENAT
Number of subjects: 132
Study 24700130 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer teaching and peer assessment (Group II)
Number of subjects: 248
Study 24700130 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician assessment (Group II)
Number of subjects: 248
Study 24700130 — intervention group
Group type: COMPARATOR
Intervention: Physician training and assessment (Group I)
Number of subjects: 248
Study 23545864 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with rSO 2 monitoring and specific interventions for cerebral desaturation
Number of subjects: 100
Study 23545864 — intervention group
Group type: COMPARATOR
Intervention: Control group with continuous rSO 2 monitoring without intervention
Number of subjects: 100
Study 19602188 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) treatment: three sets of 60 s of vibration (30 Hz, +/-4 mm) while standing in a semi-squat position
Number of subjects: 24
Study 19602188 — intervention group
Group type: COMPARATOR
Intervention: Control treatment: static squat
Number of subjects: 24
Study 17703885 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (150, 300, and 600mg/day)
Number of subjects: 40
Study 17703885 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 40
Study 17703885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 16184919 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery for colorectal cancer
Number of subjects: 0
Study 16184919 — intervention group
Group type: COMPARATOR
Intervention: Open surgery for colorectal cancer
Number of subjects: 0
Study 11963384 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 40
Study 11963384 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 40
Study 11963384 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 40
Study 9509207 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms.kg‐1
Number of subjects: 120
Study 9509207 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg
Number of subjects: 120
Study 9509207 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 120
Study 9509207 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 120
Study 8594956 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional 22-gauge Sprotte needle
Number of subjects: 40
Study 8594956 — intervention group
Group type: COMPARATOR
Intervention: Non-directional 22-gauge Quincke needle
Number of subjects: 40
Study 8594956 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranially directed catheters
Number of subjects: 40
Study 2197898 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2 mg/kg induction and 0.15 mg/kg per min maintenance with N2O/O2
Number of subjects: 30
Study 2197898 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2 mg/kg induction and enfluran maintenance with N2O/O2
Number of subjects: 30
Study 2197898 — intervention group
Group type: COMPARATOR
Intervention: Thiopental induction until loss of eyelash reflex and enfluran maintenance with N2O/O2
Number of subjects: 30
Study 2197898 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (both techniques)
Number of subjects: 30
Study 921082 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza A/New Jersey/76 whole virus vaccine administered to cancer patients
Number of subjects: 42
Study 921082 — intervention group
Group type: COMPARATOR
Intervention: Inactivated influenza A/New Jersey/76 whole virus vaccine administered to controls
Number of subjects: 42
Study 921082 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza A/New Jersey/76 whole virus vaccine administered to cancer patients at the time of chemotherapy
Number of subjects: 42
Study 921082 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza A/New Jersey/76 whole virus vaccine administered to cancer patients between chemotherapy courses
Number of subjects: 42
Study 31331617 — intervention group
Group type: EXPERIMENTAL
Intervention: LSD 6.5 μg
Number of subjects: 20
Study 31331617 — intervention group
Group type: EXPERIMENTAL
Intervention: LSD 13 μg
Number of subjects: 20